Biotechnology Stocks Trading Up: Celsion Corporation (NASDAQ:CLSN), Sinovac Biotech Ltd. (NASDAQ:SVA)
Northern, WI 05/28/2013 (GDPInsider) – Celsion Corporation (NASDAQ:CLSN) opened 0.03 cents above its previous close of 1.04 to start the day strong at 1.07. Since then the stock has moved north, currently up 7.69% on trading volume of 8.312 million – a 261.17% increase on average volume of 2.301 million. CLSN has a range of 1.05 and 1.19 and the stock is trading 88.03% below its 52-week high of 9.44. CLSN is however trading strongly on its 52-week low of 0.75, currently up 50.67%.
CLSN is an oncology drug development company which focuses on chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company recently announced that is patented application, “Method of Storing Nanoparticle Formulations,” has now been granted in the four largest markets for liver cancer globally. These markets are Japan, China, Taiwan and South Korea. The granting of these patent rights will extend CLSN’s coverage on its ThermoDox® formulation until 2026.
CLSN is trading up 18.76% on its SMA20, 16.93% on its SMA50 and has a strong RSI of 65.85.
Is CLSN a solid investment at these levels? Get exclusive data and trends here.
Sinovac Biotech Ltd. (NASDAQ:SVA) is up 16.62% after starting the day’s trading at 3.41, 0.10 cents above its previous close of 3.31. The stock has a range of 3.40 and 3.90 and is trading on relatively strong volume of 780.66K. Average volume is 490.51 and SVA is down 23.97% on its 52-week high of 5.09 and up 119.89% on its 52-week low of 1.77.
The China-based maker of biopharmaceutical products recently announced that it has obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA). The certificate was granted for SVA’s proprietary vaccines.
SVA also released unaudited Q1 2013 financial results in which the company reported a 68% increase sales to $10.1 million.
SVA is up 15.45% on its SMA20 and expects EPS this year to rise by 90.35%. The stock is just below overbought levels with a RSI of 67.29 and analysts have set a target price of 3.70.
How Should Investors Trade SVA Now? Get exclusive insights and updates here.
WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.